Sign up to save your podcasts
Or
Share No pain, no gain: Ozempic’s quest for market share
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
No pain, no gain: Ozempic’s quest for market share
The shock success of GLP-1 treatments for obesity carries massive implications for wealthy societies and manufacturers Novo Nordisk and Eli Lilly alike. In this week’s Viewsroom podcast, Breakingviews columnists discuss how this would-be jackpot has companies running to keep up.
Visit the Thomson Reuters Privacy Statement for information on our privacy and data protection practices. You may also visit megaphone.fm/adchoices to opt-out of targeted advertising.
Learn more about your ad choices. Visit megaphone.fm/adchoices
View all episodes
By Reuters
4.2
4646 ratings
The shock success of GLP-1 treatments for obesity carries massive implications for wealthy societies and manufacturers Novo Nordisk and Eli Lilly alike. In this week’s Viewsroom podcast, Breakingviews columnists discuss how this would-be jackpot has companies running to keep up.
Visit the Thomson Reuters Privacy Statement for information on our privacy and data protection practices. You may also visit megaphone.fm/adchoices to opt-out of targeted advertising.
Learn more about your ad choices. Visit megaphone.fm/adchoices
More shows like Viewsroom
View all
Global News Podcast
7,913 Listeners
Economist Podcasts
4,225 Listeners
Business Daily
523 Listeners
WSJ What’s News
4,420 Listeners
World Business Report
296 Listeners
Bloomberg Businessweek
427 Listeners
The Big View
33 Listeners
WSJ Minute Briefing
686 Listeners
FT News Briefing
684 Listeners
The World in Brief from The Economist
1,089 Listeners
Wall Street Week
64 Listeners
Reuters World News
302 Listeners
WSJ's Take On the Week
150 Listeners
The Economics Show
146 Listeners
Reuters Econ World
29 Listeners